Mga Batayang Estadistika
| CIK | 1369786 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sagent Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2017 |
SGNT / Sagent Pharmaceuticals, Inc. / HealthCor Management, L.P. - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 786692103 (CUSIP Number) December 31, 2016 |
|
| September 9, 2016 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35144 Sagent Pharmaceuticals, Inc. (Exact name of registrant as |
|
| September 2, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Rule 13d-102) (Amendment No. |
|
| August 30, 2016 |
Sagent Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 30, 2016 Registration No. |
|
| August 30, 2016 |
POS AM As filed with the Securities and Exchange Commission on August 30, 2016 Registration No. |
|
| August 29, 2016 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SAGENT PHARMACEUTICALS, INC. ARTICLE I EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SAGENT PHARMACEUTICALS, INC. ARTICLE I Name The name of the corporation is Sagent Pharmaceuticals, Inc. (the ?Corporation?). ARTICLE II Address; Registered Office and Agent The address of the Corporation?s registered office is 160 Greentree Drive, Suite 101 in the City of Dover, County of Kent, 19904; and the name of its regis |
|
| August 29, 2016 |
8-K 1 d248018d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 1-35144 98-0536317 (State or other jurisdict |
|
| August 29, 2016 |
Exhibit 3.2 BY-LAWS of SAGENT PHARMACEUTICALS, INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II STOCKHOLDERS 2 ARTICLE III DIRECTORS 6 ARTICLE IV COMMITTEES OF THE BOARD 8 ARTICLE V OFFICERS 8 ARTICLE VI INDEMNIFICATION 10 ARTICLE VII GENERAL PROVISIONS 12 i ARTICLE I DEFINITIONS As used in these By-laws, unless the context otherwise requires, the term: 1.1 |
|
| August 29, 2016 |
Sagent Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| August 29, 2016 |
EX-99.(a)(5)(viii) Exhibit (a)(5)(viii) August 29, 2016 Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc. Tokyo, Japan, August 29, 2016 ? Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) (?Nichi-Iko? or ?Parent?) today announced the results of its tender offer to purchase all of the outstandi |
|
| August 29, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 29, 2016 |
EX-99.(A)(5)(IX) 3 d181199dex99a5ix.htm EX-99.(A)(5)(IX) Exhibit (a)(5)(ix) August 29, 2016 Company name: Nichi-Iko Pharmaceutical Co., Ltd. (Stock code: 4541. TSE 1st section) Representative: Yuichi Tamura, President & CEO Inquiries: Noboru Inasaka, Managing Executive Officer and General Manager of Management Division Tel. 076-432-2121 Notification of Result of Tender Offer for Sagent Pharmaceuti |
|
| August 24, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 24, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 22, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 22, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 22, 2016 |
Exhibit (b)(2) [TRANSLATION] (Reference purpose only) BORROWER Nichi-Iko Pharmaceutical Co. |
|
| August 22, 2016 |
Exhibit (b)(2) [TRANSLATION] (Reference purpose only) BORROWER Nichi-Iko Pharmaceutical Co. |
|
| August 18, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 18, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 18, 2016 |
Sagent Pharmaceuticals SC 14D9/A SC 14D9/A 1 d241599dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, par value $0.01 per s |
|
| August 18, 2016 |
Sagent Pharmaceuticals SC 14D9/A SC 14D9/A 1 d241599dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, par value $0.01 per s |
|
| August 12, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A 1 d241439dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (N |
|
| August 12, 2016 |
Sagent Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| August 9, 2016 |
Sagent Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| August 9, 2016 |
Sagent Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| August 9, 2016 |
EX-99.(A)(5)(VII) 2 d223168dex99a5vii.htm EX-99.(A)(5)(VII) Exhibit (a)(5)(vii) August 9, 2016 Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc. Tokyo, Japan, August 9, 2016—Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) (“Nichi-Iko” or “Parent”) and Shepard Vision, Inc. (“Purchaser”) announced that the waiting pe |
|
| August 9, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 5, 2016 |
Sagent Pharmaceuticals SGNT-Q2-2016 (Quarterly Report) sgnt-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| August 5, 2016 |
Exhibit 10.2 ASSET PURCHASE AGREEMENT BETWEEN TEVA PHARMACEUTICAL INDUSTRIES LTD. AND SAGENT PHARMACEUTICALS, INC. DATED AS OF JUNE 15, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 SECTION 1.1. Definitions 1 SECTION 1.2. Interpretation 6 SECTION 1.3. Currency 6 SECTION 1.4. Incorporation by Reference and Supremacy of FTC Order 7 ARTICLE II. SALE AND PURCHASE OF TRANSFERRED ASSETS 7 SECTION |
|
| August 5, 2016 |
Exhibit 10.3 ASSET PURCHASE AGREEMENT AMONG ACTAVIS GROUP PTC EHF ACTAVIS LLC AND SAGENT PHARMACEUTICALS, INC. DATED AS OF JUNE 15, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 SECTION 1.1. Definitions 1 SECTION 1.2. Interpretation 6 SECTION 1.3. Currency 6 SECTION 1.4. Incorporation by Reference and Supremacy of FTC Order 8 ARTICLE II. SALE AND PURCHASE OF TRANSFERRED ASSETS 7 SECTION 2.1 |
|
| August 5, 2016 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of the 27th day of June, 2016 (the “Effective Date”), by and between Sagent Pharmaceuticals, Inc., a Delaware corporation (the “Employer” or the “Company”), and Donald Bullock, an individual (the “Executive”). WHEREAS, Company desires to employ Executive and to set forth certain terms and conditions of Exe |
|
| August 2, 2016 |
Sagent Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Fili |
|
| August 2, 2016 |
Notice of Commencement of Tender Offer for Sagent Pharmaceuticals, Inc.’s Shares Exhibit a(5)(vi) August 2, 2016 To whom it may concern: Company name: Nichi-Iko Pharmaceutical Co. |
|
| August 1, 2016 |
Sagent Pharmaceuticals, Inc. 1901 N. Roselle Road, Suite 700 Schaumberg, Illinois 60195 EX-99.(a)(5)(F) Exhibit (a)(5)(F) Sagent Pharmaceuticals, Inc. 1901 N. Roselle Road, Suite 700 Schaumberg, Illinois 60195 August 1, 2016 Dear Stockholder: We are pleased to inform you that, on July 10, 2016, Sagent Pharmaceuticals, Inc. (?Sagent?) entered into a definitive Agreement and Plan of Merger (the ?Merger Agreement?) with Shepard Vision, Inc., a Delaware corporation (?Purchaser?) and a di |
|
| August 1, 2016 |
EX-99.(E)(18) 3 d232122dex99e18.htm EX-99.(E)(18) EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of the 27th day of June, 2016 (the “Effective Date”), by and between Sagent Pharmaceuticals, Inc., a Delaware corporation (the “Employer” or the “Company”), and Donald Bullock, an individual (the “Executive”). WHEREAS, Company desires to employ Executive and to set fort |
|
| August 1, 2016 |
Sagent Pharmaceuticals SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 1, 2016 |
Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of SAGENT PHARMACEUTICALS, INC. |
|
| August 1, 2016 |
EX-99.(A)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defined below) and is being made to all holders of Shares. The Offer is not being made to (and no tenders will be acce |
|
| August 1, 2016 |
Exhibit (a)(5)(v) August 1, 2016 SHEPARD VISION, INC., A WHOLLY-OWNED SUBSIDIARY OF NICHI-IKO PHARMACEUTICAL CO., LTD, COMMENCES ALL-CASH TENDER OFFER OF $21.75 NET PER SHARE TO ACQUIRE ALL OUTSTANDING SHARES OF SAGENT PHARMACEUTICALS, INC. Tokyo, Japan, and Schaumburg, August 1, 2016 Shepard Vision, Inc., a Delaware corporation (the Purchaser) and a wholly-owned subsidiary of Nichi-Iko Pharma |
|
| August 1, 2016 |
[Remainder of page intentionally left blank] EX-99.(d)(3) Exhibit (d)(3) PRIVATE AND CONFIDENTIAL April 30, 2016 Nichi-Iko Pharmaceutical Co., Ltd. 6-21, Sogawa 1-chome, Toyama-shi, Toyama, Japan Dear Sirs: We understand that Nichi-Iko Pharmaceutical Co., Ltd. (the ?Recipient? or ?you?) desires to engage in certain discussions with Sagent Pharmaceuticals, Inc. (the ?Company?) in connection with your consideration of a possible negotiated tra |
|
| August 1, 2016 |
EX-99.(A)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock of SAGENT PHARMACEUTICALS, INC. at $21.75 Net per Share Pursuant to the Offer to Purchase dated August 1, 2016 by Shepard Vision, Inc., a wholly-owned subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE TIME THAT IS ONE MINUTE FOLL |
|
| August 1, 2016 |
Sagent Pharmaceuticals SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. (Name of Offeror) A Wholly-Owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Name of Offerors) (Names of Filing Persons (identify |
|
| August 1, 2016 |
Project NASA: Commitment Letter (Sagent) EX-99.(b)(1) Exhibit (b)(1) STRICTLY PRIVATE AND CONFIDENTIAL June 23, 2016 Nichi-Iko Pharmaceutical Co., Ltd. 1-6-21 Sogawa, Toyama City Toyama Prefecture, Japan Project NASA: Commitment Letter (Sagent) Ladies and Gentlemen: 1. You have advised us that you intend to enter into an Agreement and Plan of Merger (including all exhibits and schedules thereto, the ?Acquisition Agreement?) among you, yo |
|
| August 1, 2016 |
EX-99.(A)(1)(v) Exhibit (a)(1)(v) Offer To Purchase For Cash All Outstanding Shares of Common Stock of SAGENT PHARMACEUTICALS, INC. at $21.75 Net per Share Pursuant to the Offer to Purchase dated August 1, 2016 by Shepard Vision, Inc., a wholly-owned subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE TIME THAT IS ONE MINUTE FOLLOWING 11:59 P.M. (12: |
|
| August 1, 2016 |
EX-99.(D)(2) 10 d196795dex99d2.htm EX-99.(D)(2) Exhibit (d)(2) EXECUTION VERSION July 10, 2016 Nichi-Iko Pharmaceutical Co., Ltd. 6-21, Sogawa 1-chome Toyama-shi, Toyama Japan Attention: Yuichi Tamura, President & CEO Ladies and Gentlemen: Reference is made to that certain Agreement and Plan of Merger, dated as of the date hereof (as amended from time to time, the “Merger Agreement”), by and among |
|
| August 1, 2016 |
Exhibit (a)(1)(iv) Offer To Purchase For Cash All Outstanding Shares of Common Stock of SAGENT PHARMACEUTICALS, INC. |
|
| August 1, 2016 |
Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of SAGENT PHARMACEUTICALS, INC. |
|
| July 12, 2016 |
Sagent Pharmaceuticals SC14D9C SC14D9C 1 d225615dsc14d9c.htm SC14D9C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Names of Person(s) Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| July 12, 2016 |
EXHIBIT (a)(5)(i) July 12, 2016 Dear Sagent Team Members, On behalf of the Nichi-Iko Board and management, I want to emphasize how excited we are to have Sagent Pharmaceuticals join our company. |
|
| July 12, 2016 |
Sagent Pharmaceuticals SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14D?100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. a wholly owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Names of Filing Persons (Offerors)) COMMON STOCK, PAR VAL |
|
| July 11, 2016 |
Sagent Pharmaceuticals SC14D9C SC14D9C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Names of Person(s) Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 78669210 (CUSIP Number of |
|
| July 11, 2016 |
Sagent Pharmaceuticals SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14D?100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. a wholly owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Names of Filing Persons (Offerors)) COMMON STOCK, PAR VAL |
|
| July 11, 2016 |
IR presentation issued by Nichi-Iko Pharmaceutical Co., Ltd., dated as of July 11, 2016. EXHIBIT (a)(5)(i) Agreement to acquire Sagent Pharmaceuticals July 11, 2016 Copyright 2016 Nichi - Iko Pharmaceutical Co. |
|
| July 11, 2016 |
EX-99.(A)(5)(I) 2 eh1600796ex99a5i.htm EXHIBIT (A)(5)(I) EXHIBIT (a)(5)(i) July 11, 2016 Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction Transaction brings together two market leaders in generics with highly complementary product offerings Marks a significant step in Nichi-Iko’s international growth strategy through establishment of |
|
| July 11, 2016 |
Sagent Pharmaceuticals SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14D?100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SAGENT PHARMACEUTICALS, INC. (Name of Subject Company) SHEPARD VISION, INC. a wholly owned Subsidiary of NICHI-IKO PHARMACEUTICAL CO., LTD. (Names of Filing Persons (Offerors)) COMMON STOCK, PAR VAL |
|
| July 11, 2016 |
EXHIBIT (a)(5)(ii) July 11, 2016 Company name: Nichi-Iko Pharmaceutical Co., Ltd. (Stock code: 4541. TSE 1 st section) Representative: Yuichi Tamura, President & CEO Inquiries: Noboru Inasaka, Managing Executive Officer and General Manager of Management Division Tel. 076-432-2121 Notification of Agreement for Acquisition of Sagent Pharmaceuticals and Intention to Commence Tender Offer On July 11, |
|
| July 11, 2016 |
Sagent Pharmaceuticals SC14D9C SC14D9C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Sagent Pharmaceuticals, Inc. (Name of Subject Company) Sagent Pharmaceuticals, Inc. (Names of Person(s) Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 78669210 (CUSIP Number of |
|
| July 11, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction of i |
|
| July 11, 2016 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Dated as of July 10, 2016 by and among NICHI-IKO PHARMACEUTICAL CO., LTD., SHEPARD VISION, INC. and SAGENT PHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 5 ARTICLE II THE MERGER AND CLOSING 6 Section 2.1 The Merger 6 Section 2.2 Closing 6 Section 2.3 Effective Time 6 Section 2.4 |
|
| July 11, 2016 |
EX-99.1 3 d220825dex991.htm EX-99.1 Exhibit 99.1 July 11, 2016 Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction Transaction brings together two market leaders in generics with highly complementary product offerings Marks a significant step in Nichi-Iko’s international growth strategy through establishment of U.S. platform Tokyo, Japan |
|
| June 22, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdic |
|
| June 16, 2016 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS ACQUIRES PRODUCT PORTFOLIO FROM TEVA PHARMACEUTICAL INDUSTRIES LTD. Products Include Propofol for the U.S. Market; Positive Next Step in ?Triple E? Growth Strategy SCHAUMBURG, Ill., June 16, 2016 ? Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leading provider |
|
| June 16, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d191432d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (St |
|
| June 10, 2016 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdict |
|
| May 13, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction o |
|
| May 3, 2016 |
Sagent Pharmaceuticals FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 3, 2016 |
EX-10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into as of this 4th day of April, 2016 (the ?Effective Date?), by and between Sagent Pharmaceuticals, Inc., a Delaware corporation (the ?Employer? or the ?Company?), and Sean Brynjelsen, an individual (the ?Executive?). WHEREAS, Company desires to employ Executive and to set forth certain terms and conditi |
|
| May 3, 2016 |
EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into as of this 14th day of March, 2016 (the ?Effective Date?), by and between Sagent Pharmaceuticals, Inc., a Delaware corporation (the ?Employer? or the ?Company?), and J. Frank Harmon, an individual (the ?Executive?). WHEREAS, Company desires to employ Executive and to set forth certain terms and condit |
|
| May 3, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d177676d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2016 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of I |
|
| May 3, 2016 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Company Affirms 2016 Full Year Guidance Substantial Progress against Long-Term Growth Strategy; SCHAUMBURG, Ill., May 3, 2016 ? Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leading provider of affordable pharmaceuti |
|
| April 29, 2016 |
Sagent Pharmaceuticals DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 6, 2016 |
8-K 1 d158012d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (St |
|
| April 6, 2016 |
SAGENT PHARMACEUTICALS, INC. SEPARATION AGREEMENT AND RELEASE OF CLAIMS EX-10.1 Exhibit 10.1 SAGENT PHARMACEUTICALS, INC. SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (the ?Separation Agreement?) is by and between Michael Logerfo (the ?Executive?) and Sagent Pharmaceuticals, Inc. (?Sagent? or the ?Company?). WHEREAS, the Executive and the Company and, as applicable, certain of its affiliates are party to that certain Emplo |
|
| March 28, 2016 |
EX-99.1 2 d164250dex991.htm EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 3, 2016, Sagent Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Sagent”) entered into a Share Purchase Agreement with Hong Kong King-Friend Pharmaceutical Co., Ltd., a subsidiary of Nanjing King-Friend Pharmaceutical Co., Ltd., (“NKF”) pursuant to which NKF |
|
| March 28, 2016 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdi |
|
| March 23, 2016 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings SCHAUMBURG, Ill., March 23, 2016 ? Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) a leading provider of afford |
|
| March 23, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdi |
|
| March 7, 2016 |
Sagent Pharmaceuticals FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 7, 2016 |
EX-21.1 Exhibit 21.1 Company Name State of Incorporation/ Organization Country of Incorporation/ Organization Sagent Pharmaceuticals, Inc. Wyoming United States of America Sagent International LLC Cayman Islands Sagent (China) Pharmaceuticals Co. Ltd. China Omega Laboratories Limited Canada |
|
| February 25, 2016 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 Sagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings and Enhance Operational Performance SCHAUMBURG, Ill., February 25, 2016 ? Sagent Pharmaceuticals, Inc. (NASDAQ: SG |
|
| February 25, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other juri |
|
| February 16, 2016 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 16, 2016 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS Establishes Long-Term Growth Strategy to Expand Product Offerings, Enhance Operational Performance, and Execute on Strategic Acquisitions Enters Into Agreement to Sell Sagent (China) Pharmaceuticals (?SCP?) Reduc |
|
| February 16, 2016 |
SGNT / Sagent Pharmaceuticals, Inc. / HealthCor Management, L.P. - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 786692103 (CUSIP Number) December 31, 2015 |
|
| February 16, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2016 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) ( |
|
| February 10, 2016 |
SGNT / Sagent Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment sage15a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 786692103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) December 31, 2015 |
|
| February 10, 2016 |
SGNT / Sagent Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment sagentpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Sagent Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 786692103 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the |
|
| February 9, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d136947d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 |
|
| February 9, 2016 |
EX-10.1 Exhibit 10.1 SAGENT PHARMACEUTICALS, INC. AND HONG KONG KING-FRIEND INDUSTRIAL COMPANY LIMITED SHARE PURCHASE AGREEMENT DATED FEBRUARY 3, 2016 THIS SHARE PURCHASE AGREEMENT (the ?Agreement?) is entered into on February 3, 2016 (the ?Signing Date?) between: 1. SAGENT PHARMACEUTICALS, INC. (the ?Selling Shareholder?), a company duly incorporated and validly existing under the laws of Delawar |
|
| January 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Rule 13d-102) (Amendment No. |
|
| January 11, 2016 |
EX-99.1 Sagent Pharmaceuticals J.P. Morgan Healthcare Conference January 13, 2016 Exhibit 99.1 The following information contains, or may be deemed to contain, ?forward-looking statements? (as defined in and made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995). Most forward-looking statements contain words that identify them as forward-looking, |
|
| January 11, 2016 |
EX-10.1 Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT dated as of January 7, 2016 among SAGENT PHARMACEUTICALS, as U.S. Borrower OMEGA LABORATORIES LIMITED, as Canadian Borrower The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as the Administrative Agent J.P. MORGAN SECURITIES LLC, as Sole Bookrunner and Sole Lead Arranger CHASE BUSINESS CREDIT TABLE OF CONTENTS Page ARTICLE I DEFINITI |
|
| January 11, 2016 |
Sagent Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2016 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdictio |
|
| December 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction |
|
| December 30, 2015 |
SGNT / Sagent Pharmaceuticals, Inc. / HealthCor Management, L.P. - SC 13G Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No.)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 786692103 (CUSIP Number) December 23, 2015 ( |
|
| December 30, 2015 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 v427910ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint ac |
|
| December 2, 2015 |
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] EX-10.1 Exhibit 10.1 EXECUTION COPY Mr. Michael Logerfo Via Email December 2, 2015 Dear Michael, This letter (the ?Letter Amendment?) amends your employment agreement effective as of December 2, 2015 (the ?Amendment Effective Date?) with Sagent Pharmaceuticals Inc. (the ?Company?) dated as of January 20, 2011, and amended as of April 15, 2015 (the ?Employment Agreement?). All capitalized terms not |
|
| December 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction |
|
| November 3, 2015 |
EX-99.1 2 d25911dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Company Affirms 2015 Full Year Guidance Allan Oberman Assumes Role of Chief Executive Officer effective Sept 12, 2015 SCHAUMBURG, Ill., November 3, 2015 – Sagent Pharmaceuticals, Inc. (NASDA |
|
| November 3, 2015 |
Sagent Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2015 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (C |
|
| October 16, 2015 |
8-K 1 d73021d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 ( |
|
| September 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction o |
|
| August 4, 2015 |
Sagent Pharmaceuticals Board Appoints Allan Oberman as Chief Executive Officer EX-99.2 Exhibit 99.2 For Immediate Release INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 [email protected] Sagent Pharmaceuticals Board Appoints Allan Oberman as Chief Executive Officer SCHAUMBURG, Ill. ? August 3, 2015 ? Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectables market, today announced that |
|
| August 4, 2015 |
EX-99.1 2 d54116dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] SAGENT PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Company to evaluate strategic alternatives for Sagent (China) Pharmaceuticals Company modifies earnings guidance for 2015 SCHAUMBURG, Ill., August 4, 2015 – Sagent Pharmaceuticals, Inc. (NA |
|
| August 4, 2015 |
Sagent Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdi |
|
| June 11, 2015 |
Sagent Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdict |
|
| June 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction o |
|
| May 13, 2015 |
SAGENT PHARMACEUTICALS, INC. SETTLEMENT AGREEMENT AND MUTUAL RELEASE EX-10.1 Exhibit 10.1 SAGENT PHARMACEUTICALS, INC. SETTLEMENT AGREEMENT AND MUTUAL RELEASE THIS SETTLEMENT AGREEMENT (?Agreement?) and Mutual Release is made as of the 8th day of May 2015 (the ?Effective Date?), by and among Sagent Pharmaceuticals, Inc. and its parents, subsidiaries and affiliates and each of their successors, assigns, officers, directors, employees, agents, attorneys, and represen |
|
| May 13, 2015 |
Sagent Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdicti |
|
| May 8, 2015 |
Sagent Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdicti |
|
| May 8, 2015 |
SAGENT PHARMACEUTICALS, INC. SEPARATION AGREEMENT AND RELEASE OF CLAIMS Exhibit 10.1 SAGENT PHARMACEUTICALS, INC. SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (the Separation Agreement) is by and between Jeffrey Yordon (the Executive) and Sagent Pharmaceuticals, Inc. (Sagent or the Company). WHEREAS, the Executive and the Company and, as applicable, certain of its affiliates are party to that certain Employment Agr |
|
| May 8, 2015 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.2 Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO THE EMPLOYMENT AGREEMENT (this ?Amendment?) is made and entered into effective as of April 15, 2015 (the ?Amendment Effective Date?), by and between Sagent Pharmaceuticals, Inc., a Wyoming corporation (?Company?) and Michael Logerfo (the ?Executive? and together with the Company, the ?Parties?). WHEREAS, the Company and the E |
|
| May 5, 2015 |
Sagent Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2015 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2015 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Revenue driven by strong base business demand and addition of Omega Laboratories; Company Affirms 2015 Full Year Guidance SCHAUMBURG, Ill., May 5, 2015 ? Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specia |
|
| April 29, 2015 |
Sagent Pharmaceuticals DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 20, 2015 |
Sagent Pharmaceuticals Appoints Michael Logerfo as President EX-99.2 Exhibit 99.2 SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 Sagent Pharmaceuticals Appoints Michael Logerfo as President SCHAUMBURG, Ill., April 16, 2015 ? Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that its current EVP and Chief Legal Officer Michael Logerfo |
|
| April 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction of |
|
| April 20, 2015 |
Shlomo Yanai Joins Sagent Pharmaceuticals Board of Directors EX-99.1 Exhibit 99.1 SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 Shlomo Yanai Joins Sagent Pharmaceuticals Board of Directors SCHAUMBURG, Ill., April 16, 2015 ? Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Shlomo Yanai has been appointed to its Board of Director |
|
| April 10, 2015 |
Sagent Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction |
|
| April 10, 2015 |
EX-10.3 Exhibit 10.3 GUARANTY This GUARANTY, dated as of April 6, 2015 (this ?Guaranty?), is made by each of Sagent Pharmaceuticals, Inc., a Delaware corporation (?Sagent?), and Sagent Pharmaceuticals, a Wyoming corporation (the ?Company?; together with Sagent, collectively, the ?Guarantors? and individually, each a ?Guarantor?), for the benefit of JPMorgan Chase Bank, N.A. (?JPMC?), and each of t |
|
| April 10, 2015 |
Fixed Assets Committed Loan Facility Offer Letter EX-10.1 Exhibit 10.1 April 6, 2015 Sagent (China) Pharmaceuticals Co., Ltd. Attention: Mrs. Amy Wang Room 302, Building 2, No. 8 Kexin Road, West Park, Chengdu High-tech Zone, Chengdu, Sichuan Province, PRC Dear Sirs/Madam, Fixed Assets Committed Loan Facility Offer Letter JPMorgan Chase Bank (China) Company Limited, Shanghai Branch, (the ?Bank?) is pleased to make available to Sagent (China) Phar |
|
| April 10, 2015 |
AMENDMENT NO. 1 TO CREDIT AGREEMENT EX-10.2 3 d907678dex102.htm EX-10.2 Exhibit 10.2 AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT NO. 1 TO CREDIT AGREEMENT (this “Amendment”) is dated as of April 6, 2015, and is entered into by and among SAGENT PHARMACEUTICALS, a Wyoming corporation (“Borrower”), JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”) and the Lenders. W I T N E S S E T |
|
| March 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction of |
|
| March 26, 2015 |
EX-99.1 Exhibit 99.1 SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS ANNOUNCES LEADERSHIP CHANGES ?Jeffrey Yordon Retires as Chairman and CEO; Board Member, Frank Kung, Ph.D. Appointed Chairman? ?Board Launches Search for Permanent CEO? ?Company Reiterates its Guidance Range for 2015? SCHAUMBURG, Ill., March 26, 2015 ? The Board of Directors of Sagent |
|
| March 12, 2015 |
CORRESP March 12, 2015 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Sagent Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed March 7, 2014 Form 10-Q for the Quarterly Period Ended September 30, 2014 File No. 001-35144 Dear Mr. Rosenbe |
|
| March 4, 2015 |
SGNT / Sagent Pharmaceuticals, Inc. CORRESP - - CORRESP March 4, 2015 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Sagent Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed March 7, 2014 Form 10-Q for the Quarterly Period Ended September 30, 2014 File No. 001-35144 Dear Mr. Rosenber |
|
| February 19, 2015 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2014 RESULTS Record quarterly revenue primarily driven by new product launches and Oct. 1 addition of Omega Laboratories Full year results exceed updated Fiscal Year 2014 earnings guidance SCHAUMBURG, Ill., February 19, 2015 |
|
| February 19, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2015 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 10, 2015 |
SGNT / Sagent Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment sagentpharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Sagent Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 786692103 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropria |
|
| February 5, 2015 |
SGNT / Sagent Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment sage14a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 786692103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) December 31, 2014 |
|
| January 16, 2015 |
SGNT / Sagent Pharmaceuticals, Inc. CORRESP - - CORRESP January 16, 2015 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Sagent Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed March 7, 2014 Form 10-Q for the Quarterly Period Ended September 30, 2014 File No. 001-35144 Dear Mr. Rosen |
|
| January 12, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdicti |
|
| January 12, 2015 |
EX-99.1 Sagent Pharmaceuticals 33 rd Annual JP Morgan Healthcare Conference January 14, 2015 A Global Pharmaceutical Company Exhibit 99.1 2 Disclaimer Statements contained in this presentation contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this presentation are forward-looking statements within the |
|
| December 22, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. CORRESP - - CORRESP December 22, 2014 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Sagent Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed March 7, 2014 Form 10-Q for the Quarterly Period Ended September 30, 2014 File No. 001-35144 Dear Mr. Rose |
|
| December 12, 2014 |
Financial Statements and Exhibits Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2014 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other ju |
|
| December 12, 2014 |
EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 30, 2013, Sagent Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Sagent”) entered into a Share Purchase Agreement with Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd. (“Kanghong”) pursuant to which the Company agreed to acquire Kanghong’s 50% interest in Kanghong Sagent (Chengdu) Pharmaceu |
|
| December 12, 2014 |
EX-99.2 4 d834861dex992.htm EX-99.2 Exhibit 99.2 Consolidated Financial Statements of 7685947 CANADA INC. Year ended December 31, 2013 INDEPENDENT AUDITORS’ REPORT To the Board of Directors of 7685947 Canada Inc. We have audited the accompanying consolidated financial statements of 7685947 Canada Inc., which comprise the consolidated balance sheet as at December 31, 2013, and the consolidated stat |
|
| December 12, 2014 |
EX-99.3 5 d834861dex993.htm EX-99.3 Exhibit 99.3 Condensed Consolidated Interim Financial Statements of (Unaudited) 7685947 CANADA INC. Nine-month periods ended September 30, 2014 and 2013 7685947 CANADA INC. Condensed Consolidated Interim Financial Statements (Unaudited) Nine-month periods ended September 30, 2014 and 2013 Financial Statements Condensed Consolidated Interim Balance Sheet 1 Conden |
|
| December 10, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment sage14a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 786692103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) November 30, 2014 |
|
| November 19, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2014 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdict |
|
| November 7, 2014 |
EX-4.3 Exhibit 4.3 INDENTURE Dated as of [ ] between SAGENT PHARMACEUTICALS, INC. and U.S. BANK NATIONAL ASSOCIATION, as Trustee PROVIDING FOR THE ISSUANCE OF DEBT SECURITIES CROSS REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.10 (b) 7.10 (c) N.A. 311 (a) 7.11 (b) 7.11 (c) N.A. 312 (a) 2.05 (b) 11.03 (c) 11.03 313 (a) 7. |
|
| November 7, 2014 |
EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ¨ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer |
|
| November 7, 2014 |
EX-12.1 Exhibit 12.1 Sagent Pharmaceuticals, Inc. Ratio of Earnings to Fixed Charges Nine months ended 9/30/14 Year ended 12/31/13 Year ended 12/31/12 Year ended 12/31/11 Year ended 12/31/10 Year ended 12/31/09 Earnings (loss) before income taxes $ 12,888 $ 30,489 $ (16,817 ) $ (26,422 ) $ (24,495 ) $ (30,536 ) Add / (Deduct) Equity in net earnings (loss) of 50% or less owned affiliates (2,476 ) ( |
|
| November 7, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. S-3 - - FORM S-3 FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2014 No. |
|
| November 4, 2014 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Financial performance demonstrates continued positive momentum; Company updates guidance to reflect impact of recent acquisition of Omega Laboratories Limited SCHAUMBURG, Ill., November 4, 2014 – Sagent Pharmaceutical |
|
| November 4, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2014 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 2, 2014 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories Expands Sagent’s Global Footprint, Product Portfolio and Industry Leading Development Pipeline Expected to be Immediately Accretive to Cash Earnings SCHAUMBURG, Ill., October 1, 2014 – Sagent Pharmaceuticals, Inc. (NAS |
|
| October 2, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2014 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdictio |
|
| October 2, 2014 |
EX-10.1 2 d798511dex101.htm EX-10.1 Exhibit 10.1 SHARE PURCHASE AGREEMENT Among: FRANÇOIS ANGERS KAMILIA MEKHAIL-ISHAK FIDUCIE AGEMO FIDUCIE FAMILIALE MEKHAIL-ISHAK JEAN E. CLERK, Q.C. CAISSE DE DÉPÔT ET PLACEMENT DU QUÉBEC PIERRE BLEAU OLIVIER LAURENDEAU MARGUERITE DORION RICHARD VALLÉE JEAN FLEURY 7685939 CANADA INC. As Vendors And: SAGENT ACQUISITION CORP. As Purchaser SAGENT PHARMACEUTICALS, I |
|
| July 30, 2014 |
EX-99.1 2 d765040dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] SAGENT PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Company affirms upper end of 2014 guidance range SCHAUMBURG, Ill., July 30, 2014 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphas |
|
| July 30, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2014 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 13, 2014 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2014 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction |
|
| May 12, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment sage14a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 786692103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) April 30, 2014 (Da |
|
| May 6, 2014 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Record quarterly revenue driven by a combination of base business demand and products launched over the last twelve months SCHAUMBURG, Ill., May 6, 2014 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of speci |
|
| May 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2014 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2014 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 7, 2014 |
Sagent Pharmaceuticals FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 1-35144 Sagent Pharmaceuticals, Inc. (Exa |
|
| February 14, 2014 |
Page 1 of 11 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2014 |
Page 11 of 11 Pages Exhibit 1 Joint Filing Agreement We, the signatories of the statement on Schedule 13G to which this Agreement is attached, hereby agree that such statement is, and any amendments thereto filed by any of us will be, filed on behalf of each of us. |
|
| February 14, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G/A 1 e611867sc13ga-sagent.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 786692103 (CUSIP Number) Dece |
|
| February 13, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) Calendar Year 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 13, 2014 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking Division (the "Investment Banking Division") and the Alternative Investments business (the "AI Business") and U.S. private client services |
|
| February 11, 2014 |
SGNT / Sagent Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment sage13a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 786692103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) December 31, 2013 |
|
| February 11, 2014 |
EX-99.1 2 d673603dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2013 RESULTS Record quarterly revenue driven by new product launches; Record annual profitability drives results to exceed updated Fiscal Year 2013 earnings guidance SCHAUMBURG, Ill., February 11, |
|
| February 11, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2014 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) ( |
|
| January 14, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2014 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other juris |
|
| January 14, 2014 |
EX-99.1 Sagent Pharmaceuticals 32 nd Annual J.P. Morgan Healthcare Conference January 15, 2014 A Global Pharmaceutical Company Exhibit 99.1 2 Disclaimer The following information contains, or may be deemed to contain, “forward-looking statements” (as defined in and made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995). Most forward-looking statem |
|
| January 10, 2014 |
CORRESP January 10, 2014 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Sagent Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 18, 2013 File No. 001-35144 Dear Mr. Rosenberg: On behalf of Sagent Pharmaceuticals, Inc. (the “Compa |
|
| January 7, 2014 |
Termination of a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2014 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisd |
|
| December 17, 2013 |
CORRESP December 17, 2013 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Sagent Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 18, 2013 File No. 001-35144 Dear Mr. Rosenberg: We are in receipt of the letter from the staff of th |
|
| November 5, 2013 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Record revenue and strong margin drive performance; Company confirms 2013 Guidance SCHAUMBURG, Ill., November 5, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) today announced financial results for the quarter end |
|
| November 5, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2013 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (C |
|
| October 9, 2013 |
SGNT / Sagent Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment sage13in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 786692103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) September 30, 2013 |
|
| September 24, 2013 |
SECOND LOAN MODIFICATION AGREEMENT EX-10.1 Exhibit 10.1 SECOND LOAN MODIFICATION AGREEMENT This Second Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of September 23, 2013, by and among (a) SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 230 West Monroe, Suite 720, |
|
| September 24, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2013 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 17, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Rule 13d-102) (Amendment No. |
|
| September 16, 2013 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] SAGENT PHARMACEUTICALS ANNOUNCES UPSIZING AND PRICING OF OFFERING OF 4,600,000 SHARES OF COMMON STOCK SCHAUMBURG, Ill., September 10, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today anno |
|
| September 16, 2013 |
Information Relating to Part II, Item 14. Other Expenses of Issuance and Distribution. EX-99.2 5 d596819dex992.htm EX-99.2 Exhibit 99.2 Information Relating to Part II, Item 14. Other Expenses of Issuance and Distribution. The following is a statement of the expenses incurred or expected to be incurred through the date hereof, other than underwriting discounts and commissions, to be paid solely by Sagent Pharmaceuticals, Inc. (the “Company”), in connection with the issuance and dist |
|
| September 16, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2013 Sagent Pharmaceuticals, Inc. |
|
| September 16, 2013 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 4,600,000 Shares SAGENT PHARMACEUTICALS, INC. COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT September 10, 2013 September 10, 2013 Morgan Stanley & Co. LLC Jefferies LLC Merrill Lynch, Pierce, Fenner & Smith Incorporated c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 |
|
| September 11, 2013 |
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-185645 PROSPECTUS SUPPLEMENT (To Prospectus dated January 25, 2013) 4,600,000 Shares Common Stock Sagent Pharmaceuticals, Inc. is selling 3,542,470 shares of common stock, and the selling stockholders are selling additional 1,057,530 shares of our common stock. We will not receive any of the proceeds from the shares of c |
|
| September 11, 2013 |
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-185645 PROSPECTUS SUPPLEMENT (To Prospectus dated January 25, 2013) 4,600,000 Shares Common Stock This prospectus may be used by Morgan Stanley & Co. LLC in connection with offers and sales of our common stock. Such sales may be made at prevailing market prices at the time of sale, at prices related thereto or at negotia |
|
| September 9, 2013 |
Subject to Completion, Dated September 9, 2013 4,441,627 Shares Common Stock 424B3 Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| August 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2013 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 6, 2013 |
EX-99.1 2 d580603dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] SAGENT PHARMACEUTICALS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS New Product launches drive revenue and record earnings Company increases earnings outlook for 2013 SCHAUMBURG, Ill., August 6, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader |
|
| August 5, 2013 |
EX-99.2 Exhibit 99.2 Kanghong Sagent (Chengdu) Pharmaceutical Co., Ltd. (a development stage company) Balance Sheets (Amounts in thousands of U.S. Dollars) (Unaudited) March 31, 2013 December 31, 2012 Assets Current assets: Cash and cash equivalents $ 1,055 $ 2,372 Prepaid expenses and other current assets 259 380 Inventory 1,560 965 Total current assets 2,874 3,717 Non-current assets: Property, p |
|
| August 5, 2013 |
EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 30, 2013, Sagent Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Sagent”) entered into a Share Purchase Agreement with Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd. (“Kanghong”) pursuant to which the Company agreed to acquire Kanghong’s 50% interest in Kanghong Sagent (Chengdu) Pharmaceu |
|
| August 5, 2013 |
Financial Statements and Exhibits - 8-K/A 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdicti |
|
| July 11, 2013 |
8-K 1 d567187d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2013 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (St |
|
| July 11, 2013 |
Sagent Pharmaceuticals Appoints Michael Fekete to its Board of Directors EX-99.1 2 d567187dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 Sagent Pharmaceuticals Appoints Michael Fekete to its Board of Directors SCHAUMBURG, Ill., July 11, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced |
|
| July 5, 2013 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdict |
|
| June 14, 2013 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2013 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction |
|
| May 6, 2013 |
EX-10.1 Exhibit 10.1 SAGENT PHARMACEUTICALS, INC. AND CHENGDU KANGHONG PHARMACEUTICALS (GROUP) CO. LTD SHARE PURCHASE AGREEMENT DATED APRIL 30, 2013 SPA KSCP Contents Article 1 Definitions 2 Article 2 Sale and Purchase of the Shares 5 Article 3 Purchase Price and Payments 6 Article 4 Conditions Precedent 7 Article 5 Undertakings 8 Article 6 Representations and Warranties 11 Article 7 Breach of Agr |
|
| May 6, 2013 |
EX-99.1 4 d531781dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] SAGENT PHARMACEUTICALS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Record revenue and earnings driven by new product launches SCHAUMBURG, Ill., May 6, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an |
|
| May 6, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2013 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 6, 2013 |
EX-99.2 5 d531781dex992.htm EX-99.2 Exhibit 99.2 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 [email protected] SAGENT PHARMACEUTICALS ANNOUNCES AGREEMENT TO ACQUIRE REMAINING 50% INTEREST IN CHINESE MANUFACTURING JOINT VENTURE SCHAUMBURG, Ill., May 6, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis o |
|
| May 6, 2013 |
EX-10.2 Exhibit 10.2 Share Pledge Agreement KSCP SHARE PLEDGE AGREEMENT This Share Pledge Agreement (hereinafter this “Agreement”) is dated April 30, 2013, and is entered into by and between CHENGDU KANGHONG PHARMACEUTICALS (GROUP) CO. LTD (the “Pledgee”), and SAGENT PHARMACEUTICALS, INC. (the “Pledgor”), a shareholder of KANGHONG SAGENT (CHENGDU) PHARMACEUTICAL CORPORATION LIMITED (“KSCP”). WHERE |
|
| April 30, 2013 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 20, 2013 |
Sagent Pharmaceuticals Appoints James M. Hussey as President EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 Sagent Pharmaceuticals Appoints James M. Hussey as President SCHAUMBURG, Ill., March 19, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that its Board of Directors has appoint |
|
| March 20, 2013 |
8-K 1 d505380d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2013 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (S |
|
| March 8, 2013 |
8-K 1 d499321d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2013 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 1-35144 98-0536317 (State or other jurisdictio |
|
| March 5, 2013 |
SAGENT PHARMACEUTICALS ANNOUNCES AMENDMENT TO SUPPLY AGREEMENT WITH ACTAVIS, INC. EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS ANNOUNCES AMENDMENT TO SUPPLY AGREEMENT WITH ACTAVIS, INC. SCHAUMBURG, Ill., March 5, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader in specialty injectable pharmaceutical products, today announced the signing of an amendment to its Manufacturing a |
|
| March 5, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2013 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 14, 2013 |
SGNT / Sagent Pharmaceuticals, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) Calendar Year 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 14, 2013 |
Page 1 of 10 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2013 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking Division (the "Investment Banking Division") and the Alternative Investments business (the "AI Business") and U.S. private client services |
|
| February 14, 2013 |
SGNT / Sagent Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G/A 1 e610566sc13ga-sagent.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 786692103 (CUSIP Number) Dece |
|
| February 14, 2013 |
Exhibit 1 Joint Filing Agreement We, the signatories of the statement on Schedule 13G to which this Agreement is attached, hereby agree that such statement is, and any amendments thereto filed by any of us will be, filed on behalf of each of us. |
|
| February 14, 2013 |
Sagent Pharmaceuticals, Inc. Press Release, dated February 14, 2013. Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2012 RESULTS Record quarterly revenue and earnings driven by new product launches Company achieves revised Fiscal Year 2012 Guidance SCHAUMBURG, Ill., February 14, |
|
| February 14, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2013 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) ( |
|
| February 5, 2013 |
Acceleration Request Letter Sagent Pharmaceuticals, Inc. 1901 North Roselle Road, Suite 700 Schaumburg, Illinois 60195 February 5, 2013 Via EDGAR Submission Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Jennifer Riegel Scot Foley Re: Sagent Pharmaceuticals, Inc. Registration Statement on Form S-3 SEC File No. 333-185645 Ladies and Gentlemen: |
|
| January 25, 2013 |
- AMENDMENT NUMBER 1 TO FORM S-3 Amendment Number 1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on January 25, 2013 No. |
|
| January 25, 2013 |
300 North LaSalle Street Chicago, Illinois 60654 Gerald T. Nowak, P.C. To Call Writer Directly: (312) 862-2075 [email protected] (312) 862-2000 www.kirkland.com Facsimile: (312) 862-2200 January 25, 2013 Via EDGAR Submission and Overnight Courier Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Jennifer Riegel Scot Foley Re: Sagent Pharm |
|
| December 21, 2012 |
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on December 21, 2012 No. |
|
| November 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2012 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (C |
|
| November 8, 2012 |
EX-99.1 2 d433398dex991.htm SAGENT PHARMACEUTICALS, INC. PRESS RELEASE, DATED NOVEMBER 8, 2012 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS Record revenue and product approvals drive improved performance SCHAUMBURG, Ill., November 8, 2012 – Sagent Pharmaceuticals, Inc. |
|
| September 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2012 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction of |
|
| August 22, 2012 |
SGNT / Sagent Pharmaceuticals, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| August 9, 2012 |
Sagent Pharmaceuticals, Inc. Press Release, dated August 9, 2012 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Revenue growth driven by products launched in the last twelve months Company revises guidance for 2012 SCHAUMBURG, Ill., August 9, 2012 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a |
|
| August 9, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2012 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 31, 2012 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2012 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdiction of in |
|
| May 10, 2012 |
EX-99.1 Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Revenue growth driven by products launched in the last twelve months Confirms guidance for 2012 SCHAUMBURG, Ill., May 10, 2012 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on th |
|
| May 10, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2012 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 16, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2012 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdi |
|
| April 13, 2012 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 12, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2012 Sagent Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 1-35144 Delaware 98-0536317 (State or other jurisdic |
|
| February 16, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2012 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) ( |
|
| February 16, 2012 |
Loan and Security Agreement, dated February 13, 2012 Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of February 13, 2012 (the “Effective Date”) among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 230 West Monroe, Suite 720, Chicago, Illinois 60606 (“Bank”), and (b) (i) SAGENT PHARMACEUTICALS, INC., |
|
| February 16, 2012 |
Exhibit 99.1 For Immediate Release SAGENT CONTACT: Jonathon Singer (847) 908-1605 SAGENT PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS Exceeded Goal of Doubling Revenue while Expanding Adjusted Margins Provides Outlook for Fiscal 2012 SCHAUMBURG, Ill., February 16, 2012 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) today announced financial results for the quarter and |
|
| February 16, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2012 Sagent Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 1-35144 98-0536317 (State or Other Jurisdiction of Incorporation) ( |
|
| February 14, 2012 |
SGNT / Sagent Pharmaceuticals, Inc. / Key Gate Investments Ltd - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. -)* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78669210 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2012 |
Exhibit 1 Joint Filing Agreement We, the signatories of the statement on Schedule 13G to which this Agreement is attached, hereby agree that such statement is, and any amendments thereto filed by any of us will be, filed on behalf of each of us. |
|
| February 14, 2012 |
SGNT / Sagent Pharmaceuticals, Inc. / Vivo Ventures V, LLC - SC 13G Passive Investment SC 13G 1 a12-49471sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 786692103 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 14, 2012 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 16a-3(j) and Rule 13d-1(k)(1) and under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of Schedules 13D and 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0l per share, of Sagent Pharmaceuticals, Inc. and further agree that |
|
| February 13, 2012 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking division (the "Investment Banking division"), the Alternative Investments business (the "AI Business") within the Asset Management division |
|
| February 13, 2012 |
SGNT / Sagent Pharmaceuticals, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Sagent Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 786692103 (CUSIP Number) Calendar Year 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
